PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SM ...
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.279
https://www.valueinhealthjournal.com/article/S1098-3015(18)33579-4/fulltext
Title :
PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SM ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33579-4&doi=10.1016/j.jval.2018.09.279
First page :
Section Title :
Open access? :
No
Section Order :
2126